已發(fā)表的部分文獻: 標(biāo)題:Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks.作者:Bayo J, Tran TA, Wang L, Pe?±a-Llopis S, Das AK, Martinez ED;雜志名稱:Cell Rep 標(biāo)題:A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.作者:Bayo J, Fiore EJ, Dominguez LM, Real A, Malvicini M, Rizzo M, Atorrasagasti C, Garc?-a MG, Argemi J, Martinez ED, Mazzolini GD;雜志名稱:J Hepatol 標(biāo)題:Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.作者:Duan L, Chen YA, Liang Y, Chen Z, Lu J, Fang Y, Cao J, Lu J, Zhao H, Pong RC, Hernandez E, Kapur P, Tran TAT, Smith T, Martinez ED, Ahn JM, Hsieh JT, Luo JH, Liu ZP;雜志名稱:Biomed Pharmacother 標(biāo)題:Inhibition of Jumonji demethylases reprograms severe dilated cardiomyopathy and prolongs survival.作者:Tran TA, Zhang QJ, Wang L, Gonzales C, Girard L, May H, Gillette T, Liu ZP, Martinez ED;雜志名稱:J Biol Chem 標(biāo)題:Modulation of the activity of histone lysine methyltransferases and demethylases by curcumin analog in leukaemia cells.作者:Sawesi S, Malkaram SA, Abd Elmageed ZY, Fandy TE;雜志名稱:J Cell Mol Med Epigentek 公司是全球領(lǐng)先的表觀遺傳學(xué)相關(guān)研究的技術(shù)創(chuàng)新者和產(chǎn)品開發(fā)供應(yīng)商。開發(fā)了超過700多個專利產(chǎn)品,為表觀遺傳學(xué)方面的研究和新藥研發(fā)提供全面系統(tǒng)的解決方案,涵蓋樣品制備、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、組蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等領(lǐng)域,提供小分子抑制劑、蛋白質(zhì)、抗體、以及分析試劑盒產(chǎn)品。